Monopar Therapeutics (MNPR) Operating Expenses (2017 - 2025)

Monopar Therapeutics (MNPR) has 9 years of Operating Expenses data on file, last reported at $4.1 million in Q3 2025.

• For the quarter ending Q3 2025, Operating Expenses rose 159.89% year-over-year to $4.1 million; the trailing twelve-month figure through Dec 2025 stood at $10.5 million (up 59.7% YoY), and the FY2024 full-year result was $4.6 million, changed N/A from the prior year.
• Operating Expenses improved to $4.1 million in Q3 2025, from $3.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $4.1 million in Q3 2025 to a low of $1.5 million in Q4 2024.
• A 5-year average of $2.4 million and a median of $2.4 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses sank 31.75% in 2024 and jumped 159.89% in 2025, its largest moves.
• Tracing MNPR's Operating Expenses over 5 years: stood at $2.7 million in 2021, then gained by 8.5% to $2.9 million in 2022, then fell by 28.98% to $2.1 million in 2023, then declined by 26.49% to $1.5 million in 2024, then jumped by 169.52% to $4.1 million in 2025.
• Business Quant data shows MNPR's Operating Expenses at $4.1 million in Q3 2025, $3.2 million in Q2 2025, and $3.2 million in Q1 2025.